Amgen announced that the European Commission has granted marketing authorization for IMDYLLTRA (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. This approval is based...
Amgen Inc (AMGN) reported first-quarter earnings and provided an upgraded forward outlook, driven by strong performance in its core growth franchises despite headwinds from legacy product decline and regulatory uncertainties. Total product sales grew 4% year over year, totaling approximately $13.7 billion, fueled primarily by...
Amgen Inc. shares rose 4.34% to close at $410.24 on September 22, 2026, driven by positive Phase 3 trial data for its drug candidate dazodalibep in Sjogren's disease. The OASIZ 301 study met its primary endpoint in adults with moderate-to-severe Sjogren's disease, significantly strengthening the...
Amgen Inc. reported second-quarter 2012 financial results showing a 13% revenue increase to $4.5 billion and adjusted earnings rising 34% to $1.83 per share, significantly beating Thomson Reuters estimates of $1.54 EPS and $4.08 billion in revenue. The company raised its full-year 2012 guidance for...
A U.S. jury in Delaware has ruled that Amgen Inc. and its subsidiary Teneobio willfully infringed a key patent held by Harbour BioMed regarding antibody-discovery technology. The verdict, delivered following a trial that began June 8, 2026, found the defendants liable for patent infringement related...
Amgen Inc. stock closed at USD 418.60 on September 28, 2026, representing a gain of 0.96% from the previous close of USD 414.61. The trading activity reflects ongoing investor interest in the biotechnology firm's pipeline developments and regulatory milestones. Significant progress was made for Amgen's...
AIA Group Ltd increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 11.2% during the first quarter, purchasing an additional 2,815 shares to own a total of 27,962 shares valued at $9.838 million. This filing highlights continued institutional interest alongside other hedge funds like Anfield Capital...
Amgen Canada announced on April 7, 2026, that the governments of Ontario and Quebec have expanded public reimbursement for Repatha (evolocumab) to include eligible patients following an acute coronary syndrome (ACS). In Ontario, coverage under the Ontario Drug Benefit program now includes patients within 52...
Amgen announced positive topline results from a Phase 3 clinical trial for its drug TEPEZZA (teprotumumab-trbw) administered via subcutaneous injection using an on-body injector (OBI). The trial evaluated the efficacy and safety of this new delivery method in adults with moderate-to-severe active Thyroid Eye Disease...
Amgen's stock price surged on September 18, 2026, closing at $385.65 on Nasdaq, representing a gain of 1.55% from the previous session. This positive market reaction was driven primarily by the company's updated financial outlook and its commitment to shareholder returns through a robust dividend...
Wall Street analysts have issued fresh ratings on major biopharma stocks, with Jefferies initiating a Buy on Gilead Sciences and a Hold on Amgen, while JPMorgan maintained an Overweight rating on clinical-stage oncology firm Oric Pharmaceuticals. These moves reflect a nuanced market view where Gilead...
Bank of New York Mellon Corp reduced its stake in Amgen Inc. (NASDAQ: AMGN) by 2.9% in the first quarter, selling 113,573 shares to hold a position valued at approximately $1.33 billion. While several smaller institutional investors like Anfield Capital and Dogwood Wealth Management increased...
Elevation Point Wealth Partners LLC significantly increased its position in Amgen Inc. (NASDAQ:AMGN) by 91.9% in the first quarter, purchasing an additional 10,271 shares to hold a total of 21,443 shares valued at $7.545 million. Other institutional investors also adjusted their stakes, with Brighton Jones...
Amgen (AMGN) is the subject of recent market activity driven by a congressional portfolio shift and insider trading data. Representative David J. Taylor added Amgen shares to his holdings in early June, interpreted by observers as a preference for stable cash-flow generators amidst broader market...
Amgen (AMGN) stock valuation has seen a modest lift as analyst models update fair value targets from US$371.93 to US$388.03, reflecting shifts in revenue growth assumptions from 2.93% to 3.50% and net profit margin expectations rising to 25.15%. This adjustment incorporates a slightly higher future...
Amgen stock closed at $381.96 on September 14, 2026, rising 1.1 percent to outperform the broader market as the S&P 500 and Nasdaq Composite declined. The positive price movement was driven by specific regulatory developments regarding the company's oncology portfolio rather than general sector trends...
Amgen (AMGN) shares have experienced a sharp five-day decline of approximately 15%, erasing roughly $36 billion from its market capitalization and leaving the stock trading at about $204 billion. This significant drop contrasts with broader market performance, as the S&P 500 declined by only 1.2%...
Amgen stock fell approximately 1.34% to close at USD 377.35 on September 11, 2026, following a downgrade from Buy to Hold by HSBC. The bank cut its price target to USD 425 from USD 445, arguing that the stock has re-rated significantly after strong execution...
Amgen Inc. (NASDAQ: AMGN) reported solid Q2 2026 financial results with revenue reaching $10.1 billion, representing a 10% year-over-year increase. Non-GAAP EPS rose 4% to $6.29, driven by robust growth in key products which increased 26%. The company generated $3.5 billion in free cash flow...
Amgen stock experienced a severe decline of 10.1% on September 8, 2026, closing at $393.17 on the Nasdaq. This drop represents the company's steepest single-day fall in approximately 25 years, signaling significant investor concern regarding its current trajectory and market position. The primary driver of...
